Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 911

Showing 1-25 of 911 citing articles:

Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 101-126
Open Access | Times Cited: 562
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Yuze Wu, Ming Yi, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 245
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Kai Fu, Fachao Xie, Fang Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 184
Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 130
Precision Medicine: Disease Subtyping and Tailored Treatment
Richard Wang, Zhixiang Wang
Cancers (2023) Vol. 15, Iss. 15, pp. 3837-3837
Open Access | Times Cited: 126
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 558-576
Open Access | Times Cited: 119
Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
Youtong Wu, Yan Fang, Wei Qi, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 49
Open Access | Times Cited: 114
The role of cell‐penetrating peptides in potential anti‐cancer therapy
Meiling Zhou, Zou Xi, Kexin Cheng, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 86
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Pooja Gogia, Hamza Ashraf, S. Bhasin, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3886-3886
Open Access | Times Cited: 86
Natural products and drug discovery
David Newman
National Science Review (2022) Vol. 9, Iss. 11
Open Access | Times Cited: 82
Emerging Targeted Therapies for HER2-Positive Breast Cancer
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 81
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Charles M. Rudin, Martin Reck, Melissa L. Johnson, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 80
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Antibody-drug conjugates in lung cancer: dawn of a new era?
Niamh Coleman, Timothy A. Yap, John V. Heymach, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 73
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate
Anupama Samantasinghar, Naina Sunildutt, Faheem Ahmed, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114408-114408
Open Access | Times Cited: 69
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 60
Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 58
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Caili Xu, Min Zhu, Qian Wang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 51
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 49
Rise of Antibody-Drug Conjugates: The Present and Future
Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 46
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1845-1845
Open Access | Times Cited: 44
New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer, Bailey G Fitzgerald, Luis Paz‐Ares, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 803-822
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top